Drug Combination Reduces Breast Cancer Risk and Improves Metabolic Health in Rats

A University of Michigan study, led by kinesiology professor Erin Giles of the Rogel Cancer Center, found that a combination of bazedoxifene and conjugated estrogens (BZA/CE) reduced breast cancer risk and improved metabolic health in obese rats—offering a promising alternative to tamoxifen. Unlike tamoxifen, which can raise diabetes risk and trigger hot flashes, BZA/CE lowered body fat and enhanced insulin sensitivity. Read on to learn how continued research could benefit women facing breast cancer and those navigating menopause.